BACKGROUND : This study was the first multicenter phase II study of cetuximab plus folinic acid / 5-fluorouracil / irinotecan ( FOLFIRI ) in KRAS wild-type mCRC as a second-line treatment in Japan including BRAF and PIK3CA genotyping .